Perfectly normal (and exciting) drug development company.
Price is up 800 times from Summer of 2020.
Where is the problem? if it's an issue, report it to FINRA/SEC. But those who trash will not do that, because it's easy to make statements with no evidence.
Restricted shares are only 400+ million, of which 300+ million are held by officers and directors. Almost all other issued shares have aged and are free floating right now.
70 million of those restricted shares are the subject of the Savov litigation. In my opinion, the restrictions on those shares will NEVER be lifted. Using math, that means less than 100 million shares (less than 4%) are even available to mature and add to the float.